Latest News & Updates

Breaking News

28 minutes ago
Pharma Now Editorial Team

Zydus Clears DCGI Hurdle for Phase III Anti-Malarial Trials

First Oral Targeted CSU Therapy Clears EC: What Comes Next

Pharma Now Editorial Team

Alembic Clears FDA on Fingolimod, Pressing Into MS Generics

Pharma Now Editorial Team

Sun Pharma-Organon Deal Reshapes Biosimilars and Women's Health Scale

Pharma Now Editorial Team

WHO Prequalification of Novartis Pediatric Antimalarial Raises Bar for Fixed-Dose Combo Manufacturing

Pharma Now Editorial Team

Other trending news you may like to read

Zydus Clears DCGI Hurdle for Phase III Anti-Malarial Trials

Zydus wins DCGI nod for Phase III trials of oral anti-malarial Zintrodiazine across multi-centre, active-comparator studies.

Pharma Now Editorial Team

First Oral Targeted CSU Therapy Clears EC: What Comes Next

Novartis's remibrutinib becomes Europe's first oral targeted CSU therapy, with no lab monitoring required and CHMP backing.

Pharma Now Editorial Team

Alembic Clears FDA on Fingolimod, Pressing Into MS Generics

Alembic wins FDA final approval for Fingolimod 0.5 mg capsules, a generic equivalent to Novartis's Gilenya, advancing Indian generics in MS therapy.

Pharma Now Editorial Team

Sun Pharma-Organon Deal Reshapes Biosimilars and Women's Health Scale

Sun Pharma's $11.75B all-cash Organon deal expands biosimilars and women's health scale, raising GMP harmonization demands across a combined global network.

Pharma Now Editorial Team